| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000011864 |
| Receipt No. | R000008208 |
| Official scientific title of the study | Comparison of effects of a DPP-4 inhibitor and an alpha-glucosidase inhibitor on visceral fat and oxidative stress in type 2 diabetes mellitus |
| Date of disclosure of the study information | 2013/10/01 |
| Last modified on | 2017/06/02 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Comparison of effects of a DPP-4 inhibitor and an alpha-glucosidase inhibitor on visceral fat and oxidative stress in type 2 diabetes mellitus | |
| Title of the study (Brief title) | Comparison of effects of a DPP-4 inhibitor and an alpha-glucosidase inhibitor on visceral fat and oxidative stress in type 2 diabetes mellitus | |
| Region |
|
|
| Condition | ||
| Condition | type 2 diabetes mellitus | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the effects of a DPP-4 inhibitor and an alpha-glucosidase inhibitor on visceral fat and oxidative stress in type 2 diabetes mellitus |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Visceral fat mass and oxidative stress |
| Key secondary outcomes | 1) HbA1c
2) high sensitive CRP 3) urinary protein/creatinine ratio, urinary albumin/creatinine ratio, eGFR 4) renin angiotensin system: plasma renin activity, plasma aldosterone concentration, plasma prorenin concentration, plasma soluble (pro) renin receptor, urinary prorenin excretion, urinary (pro)renin excretion 5) body weight, waist circumference, adiponectin 6) endothelial function: flow mediated dilation and nitroglycerin mediated dilation 7) atherosclerosis: CAVI and AI |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is considered as a block. |
| Blocking | YES |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | treatment with sitagliptin | |
| Interventions/Control_2 | treatment with acarbose | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | - patients with diabetes mellitus
- HbA1c (JDS) of 6.1 to 8.0% - under treatment with 1) diet therapy and exercise, 2) sulphonylurea, 3) metformin, or 4) suophnylurea and metformin |
|||
| Key exclusion criteria | allergy to sitagliptin or acarbose
|
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Atsuhiro Ichihara |
| Organization | Tokyo Women's Medical University |
| Division name | Department of Medicine II, Endocrinology and Hypertension |
| Address | 8-1 Kawada-cho, Shinjuku-ku, Tokyo |
| TEL | 03-3353-8111 |
| smorimoto@endm.twmu.ac.jp | |
| Public contact | |
| Name of contact person | Satoshi Morimoto |
| Organization | Tokyo Women's Medical University |
| Division name | Department of Medicine II, Endocrinology and Hypertension |
| Address | 8-1 Kawada-cho, Shinjuku-ku, Tokyo |
| TEL | 03-3353-8111 |
| Homepage URL | |
| smorimoto@endm.twmu.ac.jp | |
| Sponsor | |
| Institute | Tokyo Women's Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Tokyo Women's Medical University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京女子医科大学、東京都
Tokyo Women's Medical University, Tokyo |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008208 |